|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial |
journalArticle |
2016 |
Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G. |
|
Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives |
journalArticle |
2015 |
Mirghani, H.; Amen, F.; Blanchard, P.; Moreau, F.; Guigay, J.; Hartl, D. M.; Lacau St Guily, J. |
|
The rising prevalence of chronic myeloid leukemia in France |
journalArticle |
2018 |
Delord, M.; Foulon, S.; Cayuela, J. M.; Rousselot, P.; Bonastre, J. |
|
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents |
journalArticle |
2017 |
Azan, A.; Caspers, P. J.; Bakker Schut, T. C.; Roy, S.; Boutros, C.; Mateus, C.; Routier, E.; Besse, B.; Planchard, D.; Seck, A.; Kamsu Kom, N.; Tomasic, G.; Koljenovic, S.; Noordhoek Hegt, V.; Texier, M.; Lanoy, E.; Eggermont, A. M.; Paci, A.; Robert, C.; Puppels, G. J.; Mir, L. M. |
|
[Individualization of dose and fractionation of radiotherapy for head and neck cancers] |
journalArticle |
2019 |
Blanchard, P.; Biau, J.; Castelli, J.; Tao, Y.; Graff, P.; Nguyen, F. |
|
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort |
journalArticle |
2015 |
Chougnet, C. N.; Borget, I.; Leboulleux, S.; de la Fouchardiere, C.; Bonichon, F.; Criniere, L.; Niccoli, P.; Bardet, S.; Schneegans, O.; Zanetta, S.; Schvartz, C.; Drui, D.; Chauffert, B.; Rohmer, V.; Schlumberger, M. |
|
[Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?] |
journalArticle |
2018 |
Margier, J.; Baffert, S.; Le Corroller-Soriano, A. G. |
|
The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France |
journalArticle |
2015 |
Scotte, F.; Martelli, N.; Vainchtock, A.; Borget, I. |
|
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours |
journalArticle |
2016 |
Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K. |
|
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models |
journalArticle |
2015 |
Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P. |
|
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer |
journalArticle |
2016 |
Lamartina, L.; Ippolito, S.; Danis, M.; Bidault, F.; Borget, I.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Blanchard, P.; Terroir, M.; Deandreis, D.; Schlumberger, M.; Baudin, E.; Leboulleux, S. |
|
The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France |
journalArticle |
2015 |
Scotte, F.; Martelli, N.; Vainchtock, A.; Borget, I. |
|
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer |
journalArticle |
2015 |
Burdett, S.; Pignon, J. P.; Tierney, J.; Tribodet, H.; Stewart, L.; Le Pechoux, C.; Aupérin, A.; Le Chevalier, T.; Stephens, R. J.; Arriagada, R.; Higgins, J. P.; Johnson, D. H.; Van Meerbeeck, J.; Parmar, M. K.; Souhami, R. L.; Bergman, B.; Douillard, J. Y.; Dunant, A.; Endo, C.; Girling, D.; Kato, H.; Keller, S. M.; Kimura, H.; Knuuttila, A.; Kodama, K.; Komaki, R.; Kris, M. G.; Lad, T.; Mineo, T.; Piantadosi, S.; Rosell, R.; Scagliotti, G.; Seymour, L. K.; Shepherd, F. A.; Sylvester, R.; Tada, H.; Tanaka, F.; Torri, V.; Waller, D.; Liang, Y. |
|
Phase I–II trial designs: how early should efficacy guide the dose recommendation process? |
journalArticle |
2018 |
Paoletti, X; Postel-Vinay, S |
|
Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis |
journalArticle |
2016 |
Lueza, B.; Rotolo, F.; Bonastre, J.; Pignon, J. P.; Michiels, S. |
|
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial |
journalArticle |
2015 |
Salgado, R.; Denkert, C.; Campbell, C.; Savas, P.; Nuciforo, P.; Aura, C.; de Azambuja, E.; Eidtmann, H.; Ellis, C. E.; Baselga, J.; Piccart-Gebhart, M. J.; Michiels, S.; Bradbury, I.; Sotiriou, C.; Loi, S. |
|
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? |
journalArticle |
2018 |
Bibault, J. E.; Blanchard, P. |
|
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity |
journalArticle |
2016 |
Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R. |
|
Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions |
journalArticle |
2018 |
Villa, I.; Mathieu, M. C.; Bosq, J.; Auperin, A.; Pomerol, J. F.; Lacroix-Triki, M.; Scoazec, J. Y.; Dartigues, P. |
|
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience |
journalArticle |
2016 |
Bluthgen, M. V.; Boutros, C.; Fayard, F.; Remon, J.; Planchard, D.; Besse, B. |
|
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer |
journalArticle |
2018 |
Gorphe, P.; Auperin, A.; Honart, J. F.; Ton Van, J.; El Bedoui, S.; Bidault, F.; Temam, S.; Kolb, F.; Qassemyar, Q. |
|
[Network meta-analyses: Interest and limits in oncology] |
journalArticle |
2016 |
Ribassin-Majed, L.; Pignon, J. P.; Michiels, S.; Blanchard, P. |
|
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas |
journalArticle |
2018 |
Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A. |
|
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
|
[Reirradiation for head and neck squamous cell carcinoma: Indications and results] |
journalArticle |
2019 |
Biau, J.; Moreau, J.; Blanchard, P.; Thariat, J.; Miroir, J.; Lapeyre, M. |
|
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? |
journalArticle |
2016 |
Ducreux, M.; Pignon, J. P. |
|
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries |
journalArticle |
2015 |
Cain, L. E.; Phillips, A.; Olson, A.; Sabin, C.; Jose, S.; Justice, A.; Tate, J.; Logan, R.; Robins, J. M.; Sterne, J. A.; van Sighem, A.; Reiss, P.; Young, J.; Fehr, J.; Touloumi, G.; Paparizos, V.; Esteve, A.; Casabona, J.; Monge, S.; Moreno, S.; Seng, R.; Meyer, L.; Pérez-Hoyos, S.; Muga, R.; Dabis, F.; Vandenhende, M. A.; Abgrall, S.; Costagliola, D.; Hernán, M. A. |
|
[Economic analysis of multinational clinical trials in oncology] |
journalArticle |
2018 |
Lejeune, C.; Lueza, B.; Bonastre, J. |
|
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
|
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care |
journalArticle |
2015 |
Schneider, D.; Bianchini, G.; Horgan, D.; Michiels, S.; Witjes, W.; Hills, R.; Plun-Favreau, J.; Brand, A.; Lawler, M. |
|
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review |
journalArticle |
2015 |
Chouaïd, C.; Crequit, P.; Borget, I.; Vergnenegre, A. |
|
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
|
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer |
journalArticle |
2019 |
Le Rhun, E.; Wallet, J.; Mailliez, A.; Le Deley, M. C.; Rodrigues, I.; Boulanger, T.; Lorgis, V.; Barriere, J.; Robin, Y. M.; Weller, M.; Bonneterre, J. |
|
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma |
journalArticle |
2015 |
Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E. |
|
[Editorial] |
journalArticle |
2018 |
Perrier, L. |
|
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
|
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma |
journalArticle |
2015 |
Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B. |
|
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type |
journalArticle |
2018 |
Beylot-Barry, M.; Mermin, D.; Maillard, A.; Bouabdallah, R.; Bonnet, N.; Duval-Modeste, A. B.; Mortier, L.; Ingen-Housz-Oro, S.; Ram-Wolff, C.; Barete, S.; Dalle, S.; Maubec, E.; Quereux, G.; Templier, I.; Bagot, M.; Grange, F.; Joly, P.; Vergier, B.; Vially, P. J.; Gros, A.; Pham-Ledard, A.; Frison, E.; Merlio, J. P. |
|
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group |
journalArticle |
2016 |
Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C. |
|
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life |
journalArticle |
2020 |
M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget |